Medexus Pharmaceuticals

MEDXF

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$3.62

+0.08 (+2.38%)

Market Cap

$114.6M

Exchange

Other OTC

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 9, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+62.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 19.9M (2022) → 32.3M (2026)

Medexus Pharmaceuticals is a small specialty pharmaceutical company that sells prescription drugs in Canada and the United States. Its key products include Rasuvo (a methotrexate auto-injector for rheumatoid arthritis and other conditions), Gleolan (a drug used during brain tumor surgery to help surgeons see cancer cells), and Treosulfan (used in bone marrow transplant preparation). Its main customers are hospitals, clinics, and specialty pharmacies serving patients with serious diseases.

Medexus earns revenue by selling these branded specialty drugs directly to healthcare providers and through distribution partners. The company operates primarily in North America and generates roughly $100 million or less in annual revenue, making it a micro-cap player in a competitive field. Its moat comes from holding exclusive rights to niche drugs with limited competition, but its small size means it depends heavily on a handful of products — losing market share or facing generic competition in any one of them could meaningfully hurt its financial results.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-0.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-314.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$9M/ year

↑ Rising (+7% vs prior year)

8.9% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

8.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$7M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Medexus Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

53.8%

Healthy — 53.8% gross margin

Operating Margin

7.8%

Modest — 7.8% operating margin

ROCE

2.7%

Weak — 2.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-8.3%

Shrinking sales (-8.3% YoY)

EPS YoY

-177.7%

Earnings shrinking (-177.7% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

3.7%

Thin free cash flow (3.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.45

Conservative — low debt load (0.45)

Interest Cover

1.12x

Dangerous — barely covers interest (1.1x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial